188,393 Shares in ResMed Inc. $RMD Purchased by PFA Pension Forsikringsaktieselskab

PFA Pension Forsikringsaktieselskab purchased a new position in ResMed Inc. (NYSE:RMD) during the fourth quarter, HoldingsChannel reports. The institutional investor purchased 188,393 shares of the medical equipment provider’s stock, valued at approximately $45,794,000.

Other hedge funds have also recently added to or reduced their stakes in the company. SJS Investment Consulting Inc. boosted its stake in ResMed by 1,433.3% in the 3rd quarter. SJS Investment Consulting Inc. now owns 92 shares of the medical equipment provider’s stock worth $25,000 after buying an additional 86 shares during the last quarter. Imprint Wealth LLC purchased a new position in ResMed during the third quarter worth approximately $26,000. WFA of San Diego LLC purchased a new position in ResMed during the second quarter worth approximately $26,000. ORG Partners LLC grew its stake in shares of ResMed by 181.6% during the 4th quarter. ORG Partners LLC now owns 107 shares of the medical equipment provider’s stock valued at $26,000 after buying an additional 69 shares during the period. Finally, Sunbelt Securities Inc. purchased a new stake in shares of ResMed during the 3rd quarter valued at $31,000. 54.98% of the stock is owned by institutional investors and hedge funds.

Key Headlines Impacting ResMed

Here are the key news stories impacting ResMed this week:

• Positive Sentiment: Q3 results beat and margin expansion — ResMed reported revenue up ~11% to ~$1.4B, EPS above consensus, GAAP/non‑GAAP gross margins expanded ~290 bps, strong operating cash flow and $262M returned to shareholders via buybacks/dividends. These fundamentals support longer‑term earnings growth and cash return potential. Resmed Inc. Announces Results for the Third Quarter of Fiscal Year 2026
• Positive Sentiment: Analyst bullish move — Royal Bank of Canada raised its price target to $321 and kept an outperform rating, signaling confidence in ResMed’s growth runway (this raises a sizable upside case). Benzinga
• Positive Sentiment: Dividend maintained and scheduled — Board declared a $0.60 quarterly dividend (ex‑div May 14, payable June 18), modest yield but adds to shareholder returns alongside buybacks.
• Neutral Sentiment: New CFO named — CFO Brett Sandercock will retire and Aaron Bloomer is appointed successor. Management continuity reduces execution risk, though investors will watch cadence of financial reporting under new leadership. ResMed beats quarterly profit estimates, names new CFO
• Neutral Sentiment: Strategic commentary and acquisition talk — Earnings call highlighted continued revenue growth drivers and strategic M&A/portfolio moves; useful context for longer‑term thesis but not immediate catalysts. ResMed Inc (RMD) Q3 2026 Earnings Call Highlights: Strong Revenue Growth and Strategic Acquisitions
• Negative Sentiment: Shares slipped after earnings despite the beat — Market reaction was negative post‑release, suggesting investors had higher expectations for guidance, cadence, or near‑term execution; volatility may continue as analysts digest details. RMD Stock Down Despite Q3 Earnings & Revenue Beat, Margins Rise
• Negative Sentiment: Mixed analyst reaction — Wells Fargo cut its target to $227 and assigned an equal‑weight rating, reflecting concern about near‑term upside and contributing to selling pressure for investors focused on shorter horizons. Benzinga

Analyst Ratings Changes

Several brokerages have recently issued reports on RMD. Wells Fargo & Company lowered their price objective on shares of ResMed from $270.00 to $227.00 and set an “equal weight” rating for the company in a research note on Friday. Wall Street Zen cut shares of ResMed from a “buy” rating to a “hold” rating in a research note on Saturday, March 14th. JPMorgan Chase & Co. started coverage on shares of ResMed in a research note on Wednesday, April 15th. They set an “overweight” rating for the company. KeyCorp reduced their price objective on ResMed from $302.00 to $290.00 and set an “overweight” rating on the stock in a research note on Monday, April 27th. Finally, Stifel Nicolaus boosted their target price on ResMed from $260.00 to $265.00 and gave the stock a “hold” rating in a report on Friday, January 30th. One investment analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and five have issued a Hold rating to the company’s stock. According to MarketBeat, ResMed presently has an average rating of “Moderate Buy” and a consensus target price of $286.18.

ResMed Stock Down 4.0%

Shares of NYSE:RMD opened at $205.17 on Friday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.32 and a current ratio of 3.06. ResMed Inc. has a 1 year low of $198.64 and a 1 year high of $293.81. The stock has a market capitalization of $29.89 billion, a P/E ratio of 19.79, a PEG ratio of 1.35 and a beta of 0.85. The stock has a 50-day simple moving average of $233.35 and a 200-day simple moving average of $246.50.

ResMed (NYSE:RMD) last issued its earnings results on Thursday, April 30th. The medical equipment provider reported $2.86 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.79 by $0.07. ResMed had a return on equity of 25.72% and a net margin of 27.44%.The business had revenue of $1.43 billion during the quarter, compared to analysts’ expectations of $1.42 billion. During the same quarter in the previous year, the business earned $2.37 EPS. The company’s revenue for the quarter was up 10.8% on a year-over-year basis. Equities analysts forecast that ResMed Inc. will post 11.07 earnings per share for the current year.

ResMed Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, June 18th. Stockholders of record on Thursday, May 14th will be issued a dividend of $0.60 per share. The ex-dividend date is Thursday, May 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 1.2%. ResMed’s payout ratio is presently 23.74%.

Insider Activity at ResMed

In related news, CEO Michael J. Farrell sold 4,991 shares of the business’s stock in a transaction that occurred on Monday, February 9th. The stock was sold at an average price of $273.78, for a total transaction of $1,366,435.98. Following the transaction, the chief executive officer directly owned 466,223 shares of the company’s stock, valued at approximately $127,642,532.94. The trade was a 1.06% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction that occurred on Wednesday, April 1st. The stock was sold at an average price of $225.00, for a total value of $450,000.00. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 21,023 shares of company stock worth $5,230,857 over the last three months. 0.65% of the stock is currently owned by corporate insiders.

ResMed Company Profile

ResMed (NYSE: RMD) is a global medical device and cloud-connectivity company focused on improving outcomes for people with sleep-disordered breathing and chronic respiratory conditions. Founded in 1989, the company is headquartered in San Diego, California, and develops, manufactures and distributes a range of devices and software used by patients, clinicians and providers worldwide.

ResMed’s product portfolio centers on noninvasive ventilation and sleep therapy equipment, including continuous positive airway pressure (CPAP) and bilevel devices, masks and related accessories for the treatment of obstructive sleep apnea and other respiratory disorders.